The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma

References

• Kimura H, Kawada J, Ito Y. Epstein-Barr virus-associated lymphoid malignancies: the expanding spectrum of hematopoietic neoplasms. Nagoya J Med Sci. 2013;75:169–179.
   PubMed Web of Science ®Google Scholar
• Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA. 1993;90:9150–9154.
   PubMed Web of Science ®Google Scholar
• Dirmeier U, Neuhierl B, Kilger E, et al. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Res. 2003;63:2982–2989.
   PubMed Web of Science ®Google Scholar
• Morris MA, Dawson CW, Young LS. Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol. 2009;5:811–825.
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG, Blake SMS, Floettmann JE, et al. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol. 1999;73:1023–1035.
   PubMed Web of Science ®Google Scholar
• Gires O, Kohlhuber F, Kilger E, et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 1999;18:3064–3073.
   PubMed Web of Science ®Google Scholar
• Vaysberg M, Lambert SL, Krams SM, et al. Activation of the JAK/STAT pathway in Epstein Barr Virus(+)-associated posttransplant lymphoproliferative disease: role of interferon-γ. Am J Transplant. 2009;9:2292–2302.
   PubMed Web of Science ®Google Scholar
• Scuto A, Kujawski M, Kowolik C, et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res. 2011;71:3182–3188.
   PubMed Web of Science ®Google Scholar
• Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701–3713.
   PubMed Web of Science ®Google Scholar
• Hong JY, Ko YH, Kim SJ, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a concise review and update. Curr Opin Oncol. 2015;27:392–398.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Hossain DM, Duttagupta P, et al. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood. 2016;127:1687–1700.
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang Z, Moreira D, et al. B cell lymphoma immunotherapy using TLR9-targeted oligonucleotide STAT3 inhibitors. Mol Ther. 2018;26:695–707.
   PubMed Web of Science ®Google Scholar
• Mei YP, Zhou JM, Wang Y, et al. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle. 2007;6:1379–1385.
   PubMed Web of Science ®Google Scholar
• Kawada J, Ito Y, Iwata S, et al. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Clin Cancer Res. 2014;20:5412–5422.
   PubMed Web of Science ®Google Scholar
• Lu MC, El-Shazly M, Wu TY, et al. Recent research and development of Antrodia cinnamomea. Pharmacol Ther. 2013;139:124–156.
   PubMed Web of Science ®Google Scholar
• Ao ZH, Xu ZH, Lu ZM, et al. Niuchangchih (Antrodia camphorata) and its potential in treating liver diseases. J Ethnopharmacol. 2009;121:194–212.
   PubMed Web of Science ®Google Scholar
• Liu FC, Lai MT, Chen YY, et al. Elucidating the inhibitory mechanisms of the ethanolic extract of the fruiting body of the mushroom Antrodia cinnamomea on the proliferation and migration of murine leukemia WEHI-3 cells and their tumorigenicity in a BALB/c allograft tumor model. Phytomedicine. 2013;20:874–882.
   PubMed Web of Science ®Google Scholar
• Yang HL, Kumar KJ, Kuo YT, et al. Antrodia camphorata induces G(1) cell-cycle arrest in human premyelocytic leukemia (HL-60) cells and suppresses tumor growth in athymic nude mice. Food Funct. 2014;5:2278–2288.
   PubMed Web of Science ®Google Scholar
• Lai CI, Chu YL, Ho CT, et al. Antcin K, an active triterpenoid from the fruiting bodies of basswood cultivated Antrodia cinnamomea, induces mitochondria and endoplasmic reticulum stress-mediated apoptosis in human hepatoma cells. J Tradit Complement Med. 2016;6:48–56.
   PubMedGoogle Scholar
• Huang YL, Chu YL, Ho CT, et al. Antcin K, an active triterpenoid from the fruiting bodies of basswood-cultivated Antrodia cinnamomea, inhibits metastasis via suppression of integrin-mediated adhesion, migration, and invasion in human hepatoma cells. J Agric Food Chem. 2015;63:4561–4569.
   PubMed Web of Science ®Google Scholar
• Lu ZM, Xu ZH. Antcin A contributs to anti-inflammatory effect of Niuchangchih (Antrodia camphorata). Acta Pharmacol Sin. 2011;32:981–982.
   PubMed Web of Science ®Google Scholar
• Gokila Vani M, Kumar KJ, Liao JW, et al. Antcin C from Antrodia cinnamomea protects liver cells against free radical-induced oxidative stress and apoptosis in vitro and in vivo through Nrf2-dependent mechanism. Evid Based Complement Alternat Med. 2013;2013:1.
   Google Scholar
• Chen YF, Wang SH, Chang SJ, et al. Zhankuic acid A as a novel JAK2 inhibitor for the treatment of concanavalin A-induced hepatitis. Biochem Pharmacol. 2014;91:217–230.
   PubMed Web of Science ®Google Scholar
• Shen YC, Wang YH, Chou YC, et al. Evaluation of the anti-inflammatory activity of zhankuic acids isolated from the fruiting bodies of Antrodia camphorata. Planta Med. 2004;70:310–314.
   PubMed Web of Science ®Google Scholar
• Chang MH, Ng CK, Lin YJ, et al. Identification of a promoter for the latent membrane protein 1 gene of Epstein-Barr virus that is specifically activated in human epithelial cells. DNA Cell Biol 1997;16:829–837.
   PubMed Web of Science ®Google Scholar
• Shiau AL, Lin YP, Shieh GS, et al. Development of a conditionally replicating pseudorabies virus for HER-2/neu-overexpressing bladder cancer therapy. Mol Ther. 2007;15:131–138.
   PubMed Web of Science ®Google Scholar
• Shi LS, Chao CH, Shen DY, et al. Biologically active constituents from the fruiting body of Taiwanofungus camphoratus. Bioorg Med Chem. 2011;19:677–683.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32:2601–2613.
   PubMed Web of Science ®Google Scholar
• Verstovsek S. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med. 2013;125:128–135.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol. 2013;23:415–424.
   PubMed Web of Science ®Google Scholar
• Ma J, Xing W, Coffey G, et al. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. Oncotarget. 2015;6:43881–43896.
   PubMedGoogle Scholar
• Pratt ZL, Zhang JZ, Sugden B. The Latent Membrane Protein 1 (LMP1) Oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells. J Virol. 2012;86:4380–4393.
   PubMed Web of Science ®Google Scholar
• Chen H, Hutt-Fletcher L, Cao L, et al. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J Virol. 2003;77:4139–4148.
   PubMed Web of Science ®Google Scholar
• Wang F, Tsang SF, Kurilla MG, et al. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol. 1990;64:3407–3416.
   PubMed Web of Science ®Google Scholar
• Zheng H, Li LL, Hu DS, et al. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol. 2007;4:185–196.
   PubMed Web of Science ®Google Scholar
• Snow AL, Lambert SL, Natkunam Y, et al. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol. 2006;177:3283–3293.
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1:75–82.
   PubMed Web of Science ®Google Scholar
• Rastelli J, Homig-Holzel C, Seagal J, et al. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood. 2008;111:1448–1455.
   PubMed Web of Science ®Google Scholar
• Kilger E, Kieser A, Baumann M, et al. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. Embo J. 1998;17:1700–1709.
   PubMed Web of Science ®Google Scholar
• Zimber-Strobl U, Kempkes B, Marschall G, et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. Embo J. 1996;15:7070–7078.
   PubMed Web of Science ®Google Scholar
• Saito M, Gao J, Basso K, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell. 2007;12:403.
   Web of Science ®Google Scholar
• Feng WH, Cohen JI, Fischer S, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96:1691–1702.
   PubMed Web of Science ®Google Scholar
• Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205:751–758.
   PubMed Web of Science ®Google Scholar
• Tomasson MH, Xiang Z, Walgren R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood. 2008;111:4797–4808.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009;106:9414–9418.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784–803.
   PubMed Web of Science ®Google Scholar
• Chen YF, Shiau AL, Wang SH, et al. Zhankuic acid A isolated from Taiwanofungus camphoratus is a novel selective TLR4/MD-2 antagonist with anti-inflammatory properties. J Immunol. 2014;192:2778–2786.
   PubMed Web of Science ®Google Scholar
• Katsuragi T, Iwashige A, Tsukada J. [Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis]. Rinsho Ketsueki. 2016;57:9–14. Japanese.
   PubMedGoogle Scholar
• Ishida M, Hodohara K, Yoshii M, et al. Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis. Int J Clin Exp Pathol. 2013;6:2237–2241.
   PubMed Web of Science ®Google Scholar